AML1/RUNX1 functions as a cytoplasmic attenuator of NF-κB signaling in the repression of myeloid tumors
Masahiro Nakagawa(NTT (Japan)), Mineo Kurokawa(University of Tokyo Hospital)
Cited by 60
Related Papers
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
|Leukemia|2012|440
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era
|Blood|2020|397
Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation
|Blood|2017|352
Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity
|Journal of Clinical Investigation|2014|216
Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells
|Journal of Clinical Investigation|2013|197